FcGR1a (CD64) Knockout THP-1 Cell Line

Catalog #

82191

$6,500 *

Size: 2 vials

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

FcGR1a (CD64) Knockout THP-1 Cell Line is a THP-1 cell line in which FcGR1a (Fc Gamma Receptor Ia or CD64) has been genetically removed from THP-1 cells using CRISPR/Cas9 genome editing with a lentivirus encoding CRISPR/Cas9 gene and sgRNA (single guide RNA) targeting human FcGR1a (CD64).

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

●

Synonyms

High affinity immunoglobulin gamma Fc receptor I, IgG Fc receptor I, Fc-gamma RI (FcRI), Fc-gamma RIA (FcgammaRIa), CD64A, FCGR1A, FCG1, FCGR1, IGFR1, FcGR-1A, FcγRIA, FCGRIA

●

Product Data Gallery

Genomic sequencing of FcGR1a (CD64) in the FcGR1a (CD64) Knockout THP-1 Cell Line

Expression of FcGR1a (CD64) expression in FcGR1a (CD64) Knockout THP-1 Cell Line by flow cytometry

Product Info

Storage and Usage

Citations

Host Cell Line

THP-1, human monocyte, suspension

Supplied As

Each vial contains ˃1 x 10⁶ cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)

Materials Required But Not Supplied

Name	Ordering Information
Thaw Medium 2	BPS Bioscience #60184
Growth Medium 2M	BPS Bioscience #78181

UniProt #

P12314

Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

FcGR1a (Fc Gamma Receptor Ia), also known as CD64, is a 72 kDa transmembrane glycoprotein that with CD32 and CD16 receptors form the large immunoglobulin superfamily. This protein is a high-affinity Fc-gamma receptor and plays an important role in both innate and adaptive immune responses. It can be found in monocytes, macrophages, and dendritic cells (DCs), but is absent in neutrophils under normal conditions. During infection the expression of FcGR1 is quickly increased in neutrophils, clustering in the cell membrane and allowing rapid binding and internalization of immune complexes. It mediates IgG effector functions in macrophages, triggering antibody-dependent cellular cytotoxicity (ADCC) of virus-infected cells and clearance of immune complexes. Diseases associated with FcGR1a include peritonitis and pharyngitis, but it is also linked to AML (acute monocytic leukemia) subtypes M4 and M5. Among its related pathways are ADORA2B (adenosine A2B receptor)-mediated anti-inflammatory cytokine production and regulation of actin dynamics for phagocytic cup formation. FcGR1a has been studied in the treatment of diseases related to macrophage-mediated chronic inflammation, such as rheumatoid arthritis (RA) and chronic diabetic wounds (CDW), and AML. Recently, fusion proteins made of CD64/CD16A have been used to create armed iPSC derived NK cells, resulting in sustained and robust ADCC in a mouse model. The use of FcGR1a-directed immunotoxins or cytolytic fusion proteins may open new avenues of treatment in multiple diseases linked to this protein.

References

Xu J. and Guo Y., 2020 Front Mol Biosci 7:581615.
Akinrinmade O., et al., 2017 Biomedicines 5(3): 56.

Storage/Stability

Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at [email protected] if the cells are not frozen in dry ice upon arrival.

Growth Media

For best results, the use of validated and optimized media from BPS Bioscience is highly recommended. Other preparations or formulations of media may result in suboptimal performance.

Thaw Medium 2 (BPS Bioscience #60184): RPMI 1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin.

Growth Medium 2M (BPS Bioscience #78181): RPMI 1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 1 μg/ml of Hygromycin B.

Applications

Study phenotype changes related to FcGR1a (CD64) knockout.
Introduce further CRISPR/Cas9-based genetic manipulations to understand the interplay between FcGR1a (CD64) and other partners and pathways.
Use as negative control in experiments involving CD64 related ADCC.

Shipping Temperature

-80°C

Notes

The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights.

License Disclosure
Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide
Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email [email protected].

Warnings

Avoid freeze/thaw cycles

Scientific Category

CAR T-Cell Therapy

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

FcGR1a (CD64) Knockout THP-1 Cell Line

PRODUCTS

SERVICES

RESOURCES

COMPANY